Incidence of infectious complications following transrectal ultrasound-guided prostate biopsy in Calgary, Alberta, Canada: A retrospective population-based analysis

Jan Krzysztof Rudzinski, MD;† Jun Kawakami, MD, FRCSC†

†Faculty of Medicine, University of Calgary, Calgary, AB; †Southern Alberta Institute of Urology, Calgary, AB

Cite as: Can Urol Assoc J 2014;8(5-6):e301-5. http://dx.doi.org/10.5489/cuaj.1751
Published online May 21, 2014.

Abstract

Introduction: We have seen an increased risk of infectious complications following transrectal ultrasound-guided prostate biopsy (TRUS-PB). Fluoroquinolone (FQ) antibiotics are common for prophylaxis prior to TRUS-PB. We evaluate whether increasing FQ resistance correlates with increased incidence of post-biopsy infectious complications at our institution.

Methods: We conducted a retrospective chart and electronic health record review on 927 patients who underwent TRUS-PB between January and July of 2012 in Calgary, Alberta, Canada. We prospectively collected the following variables: age, pre-biopsy prostate-specific antigen, and date of biopsy. We documented presentation to an emergency department within 30 days of TRUS-PB for infectious and non-infectious complications.

Results: Of the 927 patients, 58 patients (6.3%) were admitted to the emergency department due to post-TRUS-PB complications within 30 days post-biopsy. The most common infectious complications were sepsis in 21 patients (2.2%), followed by urinary tract infection (UTI) in 9 (0.9%), and prostatitis in 4 (0.4%). We found that 83% of the septic episodes and 66.6% of the UTIs were attributed to ciprofloxacin resistant Escherichia coli (E. coli). The incidence of non-infectious complications was as follows: urinary retention in 12 (1.2%), hematuria in 9 (0.9%), and rectal bleeding in 8 (0.8%).

Conclusion: Our results suggest an increased incidence of infectious complications caused by FQ resistant organisms following TRUS-PB. This finding could be attributed to increasing community resistance to ciprofloxacin. The current antimicrobial prophylactic regimen needs to be re-evaluated, and a novel approach may need to be considered.

Introduction

There is a rising incidence of infectious complications after transrectal ultrasound-guided prostate biopsy (TRUS-PB) in North America and Europe.1-4 This increase may be due to the global rise in antibacterial resistance.3 Infectious complications occur in about 1% to 6% of patients undergoing prostate biopsy. The most common complications include sepsis, urinary tract infection (UTI), prostatitis, and epididymo-orchitis.1,5-7 Post-biopsy infections are frequently associated with colonic fluoroquinolone (FQ) resistant Escherichia coli (E. coli) inoculated from the rectum into the urinary tract.8

The current American and Canadian Urological Association Guidelines recommend FQ antibiotics as first-line agents prior to TRUS-PB.9,10 Randomized clinical control trials have demonstrated efficacy of FQ in reducing the incidence of post-TRUS-PB sepsis.11,12 However, despite the reported effectiveness of FQ, we are currently observing a global rise in bacterial resistance to these agents.1,3,8 About 11% to 22% of males undergoing TRUS-PB harbour FQ resistant bacteria within their rectum.13-17

Regional reports from our site demonstrate a rise in ciprofloxacin resistance in community strains of E. coli from 7% to 11% over the past 5 years.18,19 In Latin America and India, the rates are as high as 75%.20,21 The global spread of the E. coli sequence type (ST131) with multiple antimicrobial resistance genes and the horizontal transfer gene are of great concern in the development of resistance to prophylactic antibiotics.22 Patient-specific risk factors for FQ resistance include increasing age, comorbidities, international travel, recent hospitalization, prior FQ exposure and urinary catheterization.1,3,13-17,23,24

The aim of our study was to characterize the prescribing patterns of prophylactic antibiotics prior to TRUS-PB in a large urban centre. We also investigate the relationship between increasing E. coli resistance rates and the incidence of infectious complications following prostate biopsy. More importantly, we aim to stimulate discussion around the potential modification of clinical practice guidelines for pre-biopsy antimicrobial prophylaxis.

Methods

Ethics approval for the study was granted by the Chair of Conjoint Health Research Ethics Board of the University of Alberta, Calgary, AB.
Calgary. We conducted a retrospective chart and electronic health record review of 927 patients who underwent TRUS-PB between January and July of 2012 at the Southern Alberta Institute of Urology (SAIU).

Pre-biopsy prescribing patterns among urologists at our institution was determined by the results of a survey inquiring about first- and second-line antibiotics prior to TRUS-PB. In addition, we inquired about the influence of patient-specific risk factors on the choice of the pre-biopsy antibacterial regimen.

All 12-core TRUS-PB were performed by radiologists at the Prostate Cancer Centre at the SAIU in Calgary, Alberta, Canada. All patients received a prescription for a 3-day course of oral antibiotic prior to undergoing their scheduled TRUS-PB. We only included patients who were scheduled to undergo their first prostate biopsy.

The variables collected prospectively included patient age, pre-biopsy prostate-specific antigen (PSA), and the date of TRUS-PB. Since previous studies have demonstrated that most serious infectious complications occur within 30 days of TRUS-PB, we documented the presentation to the emergency department and the ambulatory care centre within 1 month of the biopsy.

The variables collected retrospectively included length of stay in the hospital, need for intensive care (ICU) admission, as well as blood and urine culture results, which were then analyzed for bacterial susceptibility and resistance to antibiotics. The sensitivities and resistance rates are presented as percentages of the number of samples tested for each antibiotic.

Results

According to the survey results at the SAIU, the most common first-line agent for prophylaxis was the 3-day regimen of oral ciprofloxacin. Second-line antibiotics were oral trimetoprim-sulfamethoxazole or cephalaxin. All patients were advised to take their 3-day antibiotic regimen as follows: 1 day prior, the day of, and 1 day post-biopsy. According to our survey, 8 of 15 urologists indicated the following risk factors: prior exposure to FQ within 3 months of the scheduled biopsy, travel history to areas with a high incidence of FQ resistance, as well as close contact with relatives who travelled to regions with high rates of FQ resistance.

Over the 7-month study interval, we identified 927 patients (average age: 61.6 years) who underwent TRUS-PB at our institution. Overall, 58 (6.3%) patients were admitted to the emergency department 30 days post-TRUS-PB. We recorded a total of 71 (7.6%) complications: 40 (4.3%) infectious and 31 (3.3%) non-infectious (Fig. 1).

The most commonly observed infectious complications were sepsis in 21 patients (2.2%), followed by UTI in 9 (0.9%), prostatitis in 4 (0.4%) and fever in 2 (0.2%). There was 1 episode of peri-anal abscess, scrotal wall abscess, urethritis, and epididymo-orchitis in each of the remaining 4 patients with post-biopsy infections. Out of 9 isolated cases of UTI, 6 urine samples (66.6%) were ciprofloxacin-resistant E. coli. The most prevalent non-infectious complication was urinary retention in 12 patients (1.2%), followed by hematuria in 9 (0.9%), and rectal bleeding in 8 (0.8%).

The average septic patient was 60 years old and admitted 2.23 days post-TRUS-PB. The definition of sepsis in our analysis is the presence of documented or suspected infection with at least 2 criteria for systemic inflammatory response syndrome (SIRS).25

Of the 21 cases of sepsis, 18 cases were blood culture positive and 3 cases were blood culture negative. These 3 patients had a suspected infection and satisfied the SIRS criteria on admission to the emergency department. In addition, 13 of the septic patients had identical blood and urine culture results with identical antibacterial susceptibilities. The remaining 5 patients had positive blood culture results with a negative urine cultures (Fig. 2). The most common bacteria responsible for sepsis was E.coli. On average, septic patients were admitted for 5.1 days. There were no ICU admissions for patients admitted with sepsis.

Blood isolates were most resistant to ciprofloxacin, ampicillin, and trimetoprim-sulfamethoxazole, with resistance rates of 83.7%, 71.4%, and 50%, respectively (Table 1). Susceptibility was greatest to gentamicin at 78.6%, piperacillin-tazobactam at 78.5%, and amoxicillin-clavulain at 71.4%. Table 2 depicts the overall susceptibility and resistance rates of organisms isolated from the blood of patients admitted for sepsis. The highest resistance is noted to ciprofloxacin, ampi-
Infectious complications after TRUS-PB

cillin, norfloxacin, and TMP-SMX with rates of 87.5%, 80%, 50%, and 47.1%, respectively. Susceptibility was greatest to piperacillin-tazobactam (100%), amoxicillin-clavulanic acid (85.7%), and gentamicin (82.4%).

**Discussion**

Prostate cancer is the second most common cancer in men worldwide and most commonly diagnosed cancer among men in Canada. The 12-core TRUS-PB is the established gold standard modality for histological prostate cancer diagnosis. Currently, it is estimated that about 1 million TRUS-PB are performed annually in North America. The increasing incidence of hospitalization due to post-biopsy complications are a barrier to prostate cancer detection and active surveillance of patients with low-risk prostate cancer. The microbes responsible for most infectious complications at our centre reveal high resistance rates to the antibiotics recommended by North American Clinical Practice Guidelines.

Currently, the global incidence of post-TRUS-PB sepsis is between 0.1% and 5.0%. The rates at our institution are closer to the upper limit of the global range, with 83% of septic episodes and 66.6% of urinary tract infections caused by ciprofloxacin-resistant microbes. Carigan and colleagues found that the incidence of post-biopsy sepsis increased from 0.71% in 2002-2003 to 2.15% in 2010-2011. There are other North American reports demonstrating a rising trend in post-TRUS biopsy complications. In a large Ontario-based study, Nam and colleagues found a 4-fold rise in hospital admission rates after TRUS-PB over a 10-year study period. American data reveal an increasing trend in post-biopsy infections from 0.4% to 1.1% between 1991 and 2007. In the context of rising antibacterial resistance, it is not surprising to notice an increased incidence of post-biopsy infections at our institution.

The concerning finding in our study is the emergence of bacteria not commonly implicated in post-biopsy sepsis. As other studies have identified, E. coli and Klebsiella species were the most commonly found bacteria in post-TRUS sepsis. However, Comamonas species are gram-negative ubiquitous aerobic rods, which were never documented to cause sepsis in Canada. This bacterial species has only been reported in few case reports globally. This isolated case of sepsis was observed in a patient with extensive travel history to India 3 months prior to biopsy. There is evidence to suggest that there is increased colonization with antibiotic resistant commensal bacteria after travelling to highly endemic regions of Asia; these microbes persist in the bowel for up to 6 months post-travel. In a study by Patel and colleagues, travel history has been shown to increase the risk

| Table 1. Susceptibility and resistance of E. coli strains responsible for sepsis (n=14) |
|----------------------------------|-----------------|-----------------|
| Susceptible                      | Resistant       |
| Ampicillin*                     | 2 (14.3%)       | 10 (71.4%)      |
| Amoxicillin-clavulnic†           | 10 (71.4%)      | 2 (14.3%)       |
| Piperacillin-tazobactam§         | 11 (78.5%)      | 0 (0%)          |
| Cefazolin‡                      | 8 (57.1%)       | 3 (21.4%)       |
| Ciprofloxacin                   | 2 (14.3%)       | 12 (85.7%)      |
| Gentamicin                      | 11 (78.6%)      | 3 (21.4%)       |
| Trimethoprin-sulfamethoxazole*   | 7 (50%)         | 7 (50%)         |

Rates presented as percentages of 14 samples tested for each antibiotic. *Indicates presence of intermediate strain; †Indicates one strain not tested for susceptibility and resistance; ‡Indicates two strains not tested for susceptibility and resistance; §Indicates three strains not tested for susceptibility and resistance.

| Table 2. Overall blood culture depicting the susceptibility and resistance of all the bacterial strains responsible for sepsis |
|---------------------------------------------------|-----------------|-----------------|
| No. samples tested | Susceptibility | Resistance |
| Ampicillin         | 15             | 2 (13.3%)       | 12 (80%)*       |
| Amoxicillin-clavulnic† | 14             | 12 (85.7%)      | 2 (14.3%)       |
| Cefazolin          | 14             | 10 (71.4%)      | 3 (21.4%)*      |
| Piperacillin-tazobactam | 13             | 13 (100%)       | 0 (0%)          |
| Ciprofloxacin      | 16             | 2 (12.5%)       | 14 (87.5%)      |
| Norfloxacin        | 2              | 1 (50%)         | 1 (50%)         |
| Gentamicin         | 17             | 14 (82.4%)      | 3 (17.6%)       |
| Trimethoprin-sulfamethoxazole* | 17             | 9 (52.9%)       | 8 (47.1%)       |

Rates presented as percentages of 14 samples tested for each antibiotic. *Indicates presence of one intermediate strain.
of post-biopsy infections by 2.7: in addition, antibiotic exposure less than 4 weeks prior to TRUS biopsy increased the risk by 4. We therefore suggest conducting relevant travel history assessment prior to initiating pre-biopsy prophylaxis. Based on our results, FQ and amoxicillin antibiotics are not suitable for pre-biopsy prophylaxis, while gentamicin and piperacillin-tazobactam were the most effective in treating post-TRUS sepsis.

There have been many attempts to reduce the rate of post-TRUS-PB infectious complications. Adjunctive measures with pre-biopsy rectal swabs, enemas, and povidone iodine rectal cleanse have shown conflicting and clinically insignificant results. Currently, there are no concrete mitigating strategies to reduce the risk of post-TRUS-PB associated infections. Furthermore, there are no clinical practice guidelines on the management of post-biopsy infectious complications. Several U.S. centres have adopted a strategy to use a centre-specific tailored approach based on local antibacterial resistance patterns. However, the clinical and cost benefits of this approach have yet to be determined. In the interim, the most practical bedside approach at our centre is a patient-specific risk factor assessment with individualized antibacterial prophylaxis.

There are 2 proposed avenues to improve post-biopsy outcomes: (1) the modification and optimization of the prostate biopsy technique or (2) a change in the existing prophylaxis methodology. More and more, transperineal prostate biopsy has been conducted in men with more than 1 previously negative TRUS biopsy with persistently elevated PSA. In the meantime, individualized risk and benefit assessment, including patient comorbidities, life expectancy and suitability for treatment of potential underlying malignancy, should be carefully considered. The benefit of tailored culture directed antibacterial prophylaxis poses many methodological and logistical challenges. There is no established evidence to indicate the optimal laboratory screening technique and appropriate duration between pre-biopsy screening and prostate biopsy.

There is emerging evidence demonstrating the benefit of increasing the conventional ciprofloxacin regimen with aminoglycosides. The Canadian guidelines recommend the addition of intravenous aminoglycosides to FQ in centers with high post-biopsy UTI incidence. Earlier studies demonstrated the benefit of adding aminoglycosides to ciprofloxacin prophylaxis in centers with high FQ resistance. More recently, Adibi and colleagues conducted a randomized controlled trial demonstrating a decline in post-biopsy hospitalizations due to infections from 3.8% to 0.6% when intra-muscular (IM) gentamicin was added to the FQ regimen. With increased post-biopsy sepsis caused by highly FQ resistant microbes, we could explore the benefit of using aminoglycosides to improve the antibacterial prophylaxis or formalin disinfection of prostate biopsy needles.

The major limitation of our study is its retrospective design. We were unable to determine the medication compliance rate for the prescribed pre-biopsy regimen. Additionally, we may not have captured patients who potentially suffered from infections complications and never presented to the emergency department or an urgent care facility to seek medical attention.

The strength of our study is the inclusive nature of our data as this is the only centre, in a city of over 1 million people, performing TRUS-PB and all hospitals and urgent care facilities in the city had data available through their electronic medical records.

**Conclusions**

Our results suggest that the incidence of sepsis due to FQ resistant organisms increases following TRUS-PB compared to other centres in Canada. This finding is attributed to increasing local and global resistance to FQ antibiotics. The current antimicrobial prophylactic regimen requires re-evaluation, and novel approaches need to be investigated. While we explore the alternatives, our recommendation is for urologists to conduct a thorough pre-biopsy risk factor assessment with tailored prophylaxis prior to prostate biopsy.

**Competing interests:** Dr. Rudzinski declares no competing financial or personal interests. Dr. Kawakami has received travel fees and sponsorship from Pentapharm and Baxter.

This paper has been peer-reviewed.

**References**

Infectious complications after TRUS-PB


18. Church D, Pitout J, Gregson D. Microbiology Newsletter. 2008; Volumes 1, 2, 3.


Correspondence: Dr. Jan Krzysztof Rudzinski, Faculty of Medicine, University of Calgary, AB; janr@ualberta.ca